Nasal spray vs injection: do peptide nasal sprays work?

Peptide nasal sprays sound like a clean upgrade over needles. Spray instead of stick, no syringes, no bruises. But "easy to use" and "actually gets the drug into your body" are two different questions, and for most peptides the gap between them is huge. This guide walks through how nasal absorption really works, what the human data shows for the peptides people actually buy as sprays, and where injection still wins by a wide margin.

What "bioavailability" means and why it decides everything

Bioavailability is the fraction of a dose that reaches your bloodstream in an active form. Inject a peptide under the skin and most of it gets there. Spray it up your nose and a lot of it never makes it past the lining.

A subcutaneous injection of a typical peptide reaches the blood at roughly 65% to 95% bioavailability. The peptide goes straight into tissue, gets picked up by capillaries and lymph, and circulates. Very little is lost.

Nasal delivery is a different story. For most peptides the nasal bioavailability sits somewhere between under 1% and about 30%, and the low end is far more common than the high end. So if a spray and a shot are labeled with the same number of milligrams, the spray can deliver a tiny fraction of what the shot delivers. The label can read identical while the dose your body sees is wildly different.

That single fact drives almost everything else in this article. A nasal spray is not a "needle-free version of the same dose." It is usually a much weaker, much more variable dose unless the formulation was specifically engineered to overcome the nose's defenses.

The numbers side by side

Route	Typical bioavailability	Dose precision	Onset speed	Best suited for
Subcutaneous injection	~65-95%	High (measured volume)	Fast and predictable	Almost all therapeutic peptides
Intramuscular injection	High, similar to subcutaneous	High	Fast	Larger volumes, some hormones
Nasal spray (small peptide, optimized formula)	~10-40% (a few small drugs reach higher)	Moderate	Fast	Desmopressin, calcitonin, select neuropeptides
Nasal spray (larger or hydrophilic peptide)	Often under 1-5%	Low and variable	Variable	Generally not viable without enhancers
Oral capsule	Usually under 1-2%	Low	Slow	Very few peptides survive the gut

Treat these as ranges, not promises. The exact figure depends on the specific molecule, the formulation, and your nose on that particular day.

Why the nose is a hard place to absorb a peptide

The nasal lining looks like a shortcut to the blood. It is thin, wet, and packed with blood vessels. For small fat-friendly molecules it really is a fast route. For peptides, three problems stack up against you.

Problem 1: peptides are big and water-loving

Peptides are chains of amino acids. They are larger and more hydrophilic (water-loving) than the small drugs that cross membranes easily. The nasal lining is a barrier built to keep big water-loving molecules out, and it does its job.

The relationship is fairly clean: bioavailability drops as molecular weight climbs. Research on nasal absorption shows good uptake, often around 70%, for molecules under about 1,000 daltons, then a steep drop-off above that line. Without special help, the nasal route works best for peptides roughly 1 kDa or smaller. Peptides in the few-kilodalton range and up generally cannot reach useful blood levels through the nose at all.

For comparison: desmopressin (about 1.1 kDa, 9 amino acids) absorbs well enough to be a real nasal drug. Many popular "wellness" peptides are bigger and far less cooperative. The general rule, repeated across the literature on nasal delivery of larger drugs, is that bioavailability falls as the peptide gets heavier and more water-loving, and that hydrophilic peptides above roughly 1 kDa cross the nasal lining poorly because of both weak permeability and on-site breakdown.

Problem 2: your nose clears the spray in minutes

The nose has a built-in cleaning system called mucociliary clearance. Tiny hairs (cilia) sweep a layer of mucus toward the throat, where you swallow it. This protects you from dust and germs. It also sweeps away your spray.

Normal mucociliary transit runs about 12 to 15 minutes. Peptides that do get absorbed are taken up across the nasal lining within roughly 5 to 15 minutes. So there is a tight, unforgiving window: the drug has to cross the barrier before the nose flushes it down your throat. Anything not absorbed in that window is gone, and any swallowed peptide is then destroyed by stomach acid and gut enzymes. This is a major reason nasal bioavailability is so low and so variable. (See Nasal mucociliary clearance as a factor in nasal drug delivery, Advanced Drug Delivery Reviews, 1998.)

Problem 3: the nose digests peptides too

The nasal lining contains enzymes (peptidases) that chew up peptides on contact, the same way gut enzymes do, just less aggressively. Part of your dose is broken down before it ever crosses into the blood. Add a head cold, allergies, or congestion and the absorbing surface shrinks further, so a stuffy nose can cut an already-low dose even lower.

The evidence, peptide by peptide

This is where marketing and data part ways. "Nasal sprays" are sold for many peptides, but the quality of evidence ranges from FDA-approved to essentially none. Here is an honest grade.

PTH 1-34 (teriparatide, for osteoporosis): nasal essentially failed

This is the cleanest cautionary tale because researchers measured it directly. In a pharmacokinetic study, a 90 microgram nasal spray dose of PTH 1-34 produced a mean plasma peak (Cmax) of about 5 pg/mL. A 20 microgram subcutaneous injection produced a mean Cmax of about 253 pg/mL. The relative bioavailability of the nasal spray came out to roughly 0.26% to 1% of the injection, even though the nasal dose was more than four times larger in milligrams. (Pearson et al., Pharmaceutics, 2019; PMID 31181662.)

Read that again. Four-plus times the milligrams, and the nose delivered roughly one-hundredth to one four-hundredth of the blood level. That is the wall you are up against with a larger peptide and no permeation enhancer.

Grade: strong evidence that the unenhanced nasal route does not work for this peptide.

PT-141 (bremelanotide, for sexual arousal): the company abandoned the spray

Bremelanotide is the active drug in Vyleesi, FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. The approved product is a subcutaneous injection, 1.75 mg, given at least 45 minutes before sexual activity, no more than one dose per 24 hours and no more than eight per month. (Vyleesi FDA label.)

Here is the part the spray sellers leave out. The drug started life as a nasal spray. Palatin Technologies ran Phase 2 nasal trials, and the FDA placed them on hold in 2007 after subjects showed increased blood pressure. The company stopped nasal development in 2008 and switched to subcutaneous injection, which had a better cardiovascular profile and more consistent blood levels. The nasal route was dropped partly because bioavailability varied so much that some patients got too much (spiking blood pressure) while others got too little. (Bremelanotide, Wikipedia summary of the development history.)

So when a compounding pharmacy sells you "PT-141 nasal spray," you are buying the formulation the original developer abandoned for safety and consistency reasons, not an FDA-approved product. Marketing claims of "60-80% nasal bioavailability" for PT-141 trace back to vendor pages, not published human pharmacokinetic trials.

Grade: the injectable is FDA-approved; the nasal spray is off-label, compounded, and was discontinued in development over blood pressure and dosing variability.

Oxytocin: real but messy, and the brain claim is contested

Intranasal oxytocin is the most studied "nose-to-brain" peptide, and it is a useful lesson in honest grading. The nasal bioavailability into the bloodstream is low, around 2%. The bigger debate is whether sniffing oxytocin actually raises oxytocin in the brain in a way that drives the social and emotional effects people claim.

Some studies in animals and primates found that labeled oxytocin reaches the cerebrospinal fluid and certain brain regions after nasal dosing, supporting a direct nose-to-brain pathway. But a careful human imaging study found that oxytocin's effects on brain blood flow were explained by the rise in oxytocin in general circulation, with no sign of a "privileged" nose-to-brain shortcut compared with an intravenous dose. (Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans, Nature Communications, 2020; PMID 32127545.) A major review of the field concluded that methods have been inconsistent and that many basic questions about dose, delivery, and brain penetration remain unsettled. (Quintana et al., Molecular Psychiatry, 2021; PMID 32807845.)

Grade: nasal oxytocin reaches the body and possibly the brain, but the effect sizes and the brain-delivery claim are mixed and contested. Not a settled "it works."

Semax and Selank (Russian nootropic peptides): approved abroad, weak Western evidence

Semax and Selank were developed in Russia and are approved there as intranasal products. Semax is on Russia's list of essential medicines. There is human trial data, including a study reporting Selank produced anxiety relief comparable to a benzodiazepine over 14 days without sedation.

Be careful here. Neither is FDA-approved. Much of the human evidence is older, comes from a small number of Russian research groups, and was not run to the size and standard Western regulators expect. In the US and EU they are sold as research chemicals, not medicines. The frequent vendor claim of "high intranasal bioavailability" for these small peptides is plausible given their tiny size, but it is not backed by the kind of independent pharmacokinetic data available for approved drugs.

Grade: regionally approved and biologically plausible, but the Western evidence base is thin and largely from a single research tradition.

Where nasal peptides genuinely work: desmopressin and calcitonin

The nasal route is not hopeless. Two approved drugs prove it can work when the molecule is small and the formula is engineered for it. Desmopressin nasal spray has treated diabetes insipidus and bedwetting for decades with reliable, predictable absorption, because the molecule is small (about 1.1 kDa). Salmon calcitonin nasal spray (Miacalcin) was approved for osteoporosis, showing that even a 32-amino-acid peptide can reach useful nasal levels with the right formulation.

The difference between these and a random "research" nasal peptide is decades of formulation work, real pharmacokinetic data, and regulatory review. (Overview of intranasally delivered peptides: key considerations for pharmaceutical development, Expert Opinion on Drug Delivery, 2018; PMID 30173579.) For a broader look at how researchers measure and compare these routes, see the PubMed literature on intranasal peptide bioavailability.

Can formulation tricks rescue the nasal route?

Drug developers know the nose is hostile, so they have built tools to fight back. Three matter most.

Permeation enhancers are additives that temporarily loosen the nasal barrier so more peptide slips through. They can raise bioavailability several-fold. The catch: the same loosening that lets the drug in can irritate the lining and let other things in too, so safety has to be proven, not assumed.

Mucoadhesives are sticky materials (often gels or special polymers) that make the formulation cling to the nasal lining longer. Since the whole problem is that mucociliary clearance flushes the spray in 12 to 15 minutes, buying the drug a few extra minutes of contact time directly improves uptake.

Protease inhibitors blunt the nasal enzymes that digest peptides on contact, sparing more of the dose.

These are real, studied strategies, and they are exactly why approved nasal peptides like desmopressin and calcitonin perform far better than a plain peptide-in-saline spray. But here is the honest point for consumers: a typical compounded "research" nasal spray is usually just peptide dissolved in a simple liquid, with none of this engineering. So the bioavailability you should expect from those products is the low, unenhanced end of the range, not the optimistic numbers vendors quote from sophisticated pharmaceutical formulations.

The "nose-to-brain" pitch, examined

The most exciting claim for nasal peptides is the nose-to-brain pathway. The idea: olfactory and trigeminal nerves in the upper nose connect directly to the brain, so a peptide can bypass the blood-brain barrier and act centrally at low systemic doses. There is real science behind the concept, and review work on therapeutic peptides as nasal aerosols treats it as a legitimate research direction. (Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols, Pharmaceutics, 2022; PMID 36145618.)

But two honest caveats matter. First, the olfactory region that actually connects to the brain is a small patch high in the nasal cavity, and most of a typical spray lands lower down and never reaches it. Second, as the oxytocin debate shows, demonstrating that a molecule reaches the brain in measurable, functionally meaningful amounts in humans is genuinely hard, and the results are mixed. The pathway is real in principle. Whether your particular spray, at your dose, delivers a meaningful amount to your brain is usually unproven.

Head-to-head: nasal spray vs injection

Factor	Nasal spray	Subcutaneous injection
Bioavailability	Low and variable for most peptides (often under 5%)	High and consistent (~65-95%)
Dose accuracy	Poor; affected by congestion, technique, swallowing	Good; measured volume
Day-to-day consistency	Variable (a cold can wreck a dose)	Stable
Convenience	High; no needles	Lower; needles, sharps disposal
Pain and bruising	Minimal	Mild; some sting and occasional bruising
Blood-brain access	Possible for small peptides, but contested	Limited unless the peptide crosses normally
Regulatory status of common products	Mostly compounded or research-chemical	Some FDA-approved, many compounded
Best use case	Small approved peptides; convenience over precision	When you need a reliable, accurate dose

The pattern is clear. You trade convenience for dose accuracy and reliability. For a few small, well-formulated peptides that trade is fine. For most peptides, choosing the spray means accepting that you do not really know how much drug you are getting.

If you are still weighing routes and want a deeper primer on getting started safely, our how to start peptide therapy guide covers the basics, and the peptide reconstitution guide explains why measured injectable dosing is so much more controllable than spray dosing.

Safety: what actually changes between spray and shot

The needle is not the only safety variable. The route changes the risk profile in ways people underestimate.

Dose variability is itself a safety problem. The bremelanotide story is the clearest example: variable nasal absorption meant some users got blood-pressure spikes while others got nothing. Unpredictable dosing is dangerous in both directions.

Local nasal damage. Repeated spraying, especially of compounded products with preservatives, alcohol, or permeation enhancers, can irritate the nasal lining, cause crusting or nosebleeds, and over time damage the cilia you depend on for clearance. Damaged cilia change absorption further, so the dose drifts over weeks of use.

Compounded and research-chemical quality. Most "wellness" nasal peptides are not FDA-approved. Compounded products are not tested for the safety, effectiveness, and quality of an approved drug, and research chemicals are not made for human use at all. Purity, sterility, and actual peptide content can vary. For more on vetting sources, see our peptide vendor quality standards and best peptide vendors, third-party tested guides.

Drug interactions and conditions. Anything that raises blood pressure (like the melanocortin peptides) deserves caution if you have cardiovascular issues. A peptide that affects hormones or mood deserves a real conversation with a clinician, not a checkout button. For a broader look at what can go wrong, read peptide therapy side effects and risks.

Who a nasal peptide actually makes sense for

A nasal spray is reasonable when three things line up: the peptide is small enough to absorb nasally, the product is an actual approved or properly formulated medicine, and you value convenience over exact dosing. Desmopressin and calcitonin patients fit this. People using small neuropeptides under medical guidance may fit it.

A nasal spray is a poor choice when you need a precise, reliable dose, when the peptide is large or hydrophilic (most of them), when the product is a compounded or research-chemical knockoff of an injectable drug, or when the only evidence for "it works nasally" is a vendor's website. In those cases the injection is not just more effective, it is more predictable, which is its own kind of safety.

Bottom line: peptide nasal sprays can work, but only for the right peptide in the right formulation. For the majority of peptides being sold as sprays today, the nose throws away most of the dose, and the data backing the spray is weak. When the question is "will this actually get into my body in a known amount," injection still wins for almost everything.

Frequently Asked Questions

Do peptide nasal sprays work as well as injections?

For most peptides, no. Subcutaneous injection delivers roughly 65-95% of the dose to the bloodstream, while nasal sprays often deliver under 5% and with much more variability. A few small peptides like desmopressin absorb well nasally, but they are the exception. Same milligrams on the label does not mean same dose in your body.

Why is nasal bioavailability so low for peptides?

Three reasons stack up. Peptides are large and water-loving, so the nasal barrier blocks them. The nose clears sprays in about 12-15 minutes via mucociliary clearance, leaving a narrow absorption window. And nasal enzymes break down part of the dose on contact. Bigger peptides (above about 1 kDa) lose out the most.

Is PT-141 nasal spray FDA-approved?

No. The FDA-approved bremelanotide product, Vyleesi, is a subcutaneous injection. The nasal version was actually tested first, then dropped in 2007-2008 after blood pressure increases and inconsistent absorption. Any PT-141 nasal spray you find today is compounded or a research chemical, sold off-label, not an approved medicine.

Does the nose-to-brain pathway really deliver peptides to the brain?

Sometimes, possibly, but it is contested. The pathway is real for small peptides in animal studies, yet human evidence is mixed. A 2020 imaging study found oxytocin's brain effects were explained by circulating blood levels, not a special nasal shortcut. Most of a spray also lands too low in the nose to reach the brain-connected region.

Are compounded peptide nasal sprays safe?

They carry extra risk. Compounded and research-chemical sprays are not tested to FDA standards for purity, sterility, or actual peptide content. Variable dosing can cause too much or too little drug, repeated use can irritate or damage the nasal lining, and quality varies by source. Buy only from vetted, third-party-tested suppliers and involve a clinician.

This article is for educational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting, stopping, or changing any peptide therapy.